Latest news with #GenerationStudy
BBC News
23-04-2025
- Health
- BBC News
Norfolk and Norwich Hospital joins 'world-leading' baby study
A hospital has begun testing newborn babies for genetic conditions as part of a "world-leading" Generation Study aims to test the entire DNA – or genome - of 100,000 babies across England to check for rare illnesses that can develop later in life with the hope of speeding up diagnosis and Norfolk and Norwich University Hospital (NNUH) is one of about 30 NHS hospitals taking part in the involves midwives taking blood samples from umbilical cords shortly after birth and sending them to a laboratory to be examined. The test checks for disorders that develop in early childhood for which there are effective NHS said in some cases these diseases were curable, if caught midwife and principal investigator, Leanne Trenerry, said: "Ninety-nine per cent of women who take part will receive a letter or email telling them there is 'no condition suspected'."For the 1% of 'condition suspected' cases, families will be contacted by an appropriate NHS specialist team to provide further testing to confirm a diagnosis." Optional test At present, newborns are given a heelprick blood test that checks for nine serious conditions, including cystic part of this new study, led by Genomics England, blood samples will help diagnose many more disorders, such as haemophilia and spinal muscular NNUH said the optional test was open to all women over 16 who had a singleton pregnancy (not twins or triplets).Expectant parents would be informed about the study at their 20-week scan appointment, the hospital England said the plan was to collect evidence to determine whether genomic newborn screening should be offered to all children in company, which is government-owned, said blood samples and data would be securely kept for 16 years, and would only be accessed by approved healthcare researchers. Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
Yahoo
20-03-2025
- Business
- Yahoo
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
New agreement to support newborn health adds sequencing lab services to the existing extraction services collaboration WALTHAM, Mass., March 20, 2025--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced an agreement with Genomics England to further collaborate on the Generation Study. Under the new contract, Revvity will now also provide DNA sequencing services to help screen newborns for rare genetic conditions. This expanded relationship builds upon the previously disclosed agreement to perform DNA extraction services. Revvity will now be able to provide an integrated end-to-end solution with a localized lab facility, which will allow for accelerated extraction and sequencing services to advance the screening process for these rare conditions. The Generation Study, a research project spearheaded by Genomics England in partnership with the National Health Service, is a landmark national initiative aimed at screening up to 100,000 newborns for more than 200 rare genetic disorders. The findings will help inform future decisions on using whole genome sequencing (WGS) in newborn screening. Proactive genomic screening could help healthcare professionals identify risks for pediatric-onset conditions sooner, enabling earlier interventions and personalized care. "It is an honor to enhance our collaboration with Genomics England as we align to expand access to genomic sequencing in England. Our complete solution and localized lab facility help us deliver timely and reliable sequencing data in support of this critical program that strengthens newborn health," stated Dr. Madhuri Hegde, Revvity's senior vice president and chief scientific officer. "Revvity's expansive global laboratory network combined with our next-generation sequencing solutions and workflows for newborn screening uniquely positions us to lead this and similar initiatives, setting a standard for future programs." "This collaboration is an important step forward in our mission to generate evidence on the use of genomic sequencing in newborn screening. By working with Revvity as one of our sequencing partners for the Generation Study, we can integrate sequencing alongside extraction, streamlining the process, and generating results more efficiently, helping families get answers and access to care sooner," said Dr. Ellen Thomas, chief medical officer at Genomics England. To learn more about Revvity's newborn sequencing research solutions, please visit: About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries. Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram. About Genomics England Genomics England is a global leader in enabling genomic medicine and research, established by the United Kingdom's Department of Health and Social Care, focused on creating a world where everyone benefits from genomic healthcare. Building on the 100,000 Genomes Project, it supports the NHS's world-first national whole genome sequencing service and runs the growing National Genomic Research Library, alongside delivering numerous major genomics initiatives including the Generation Study. By connecting research and clinical care at national scale, it enables immediate healthcare benefits and advances for the future. View source version on Contacts Investor Relations: Steve Revvity Media Relations: Chet Murray(781) Genomics England Media: media@ Sign in to access your portfolio
